The Patent Finder
AP

Abbott Products GmbH

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Two patents currently held, every record listed here

6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2028. from the record

Of the 6 now held by other companies, 4 name AbbVie Inc. as their current owner, and 2 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Oct 2028
Next term end
2
Patent families

When these terms end

Each bar runs from grant to computed term end. 2012 to 2032.
US 10,072,256 Process for Separating and Determining the Viral Load in a Pancreatin Sample Oct 11, 2028
US 8,273,348 Lipase Variants for Pharmaceutical Use Nov 21, 2028
US 11,266,607 Process for the Manufacture and Use of Pancreatin Micropellet Cores Mar 6, 2029
US 9,198,871 Delayed Release Pancreatin Compositions Feb 7, 2030
US 9,080,193 Preparation of (3aS,7aR)-HEXAHYDROISOBENZOFURAN-1(3H)-ONE by Catalyzed Biological Resolution of Dimethyl CYCLOHEXANE-1,2-Dicarboxylate May 24, 2031
US 9,453,007 Hepatitis C Inhibitors and Uses Thereof Dec 16, 2031
US 9,567,355 Hepatitis C Inhibitors and Uses Thereof Dec 16, 2031
US 9,173,887 Hepatitis C Inhibitors and Uses Thereof Feb 1, 2032
20162020202420282032
Every computed term in this portfolio is shown above.Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 73 later US patents, top 1% of utility patents granted in 2022 in our data. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Ends Mar 2029 · High confidence
Also notable
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2028.
now held by Novozymes A/S
Ends Nov 2028 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jun 1, 2027
    The maintenance fee for Delayed Release Pancreatin Compositions (US 9,198,871) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 2 of 2

PatentTitleStatusExpiresConfidence
US 10,072,256Process for Separating and Determining the Viral Load in a Pancreatin Sample
In force
 · High confidence
In forceHigh confidence
US 9,198,871Delayed Release Pancreatin Compositions
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 2: 6 patents in force now held by others · 26 patents ended · 19 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited